GR3035196T3 - Method for treating multiple sclerosis - Google Patents
Method for treating multiple sclerosisInfo
- Publication number
- GR3035196T3 GR3035196T3 GR20010400014T GR20010400014T GR3035196T3 GR 3035196 T3 GR3035196 T3 GR 3035196T3 GR 20010400014 T GR20010400014 T GR 20010400014T GR 20010400014 T GR20010400014 T GR 20010400014T GR 3035196 T3 GR3035196 T3 GR 3035196T3
- Authority
- GR
- Greece
- Prior art keywords
- necrosis factor
- tumour necrosis
- multiple sclerosis
- treating multiple
- factor receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/GB1993/001614 WO1995003827A1 (en) | 1993-07-30 | 1993-07-30 | Method for treating multiple sclerosis |
Publications (1)
Publication Number | Publication Date |
---|---|
GR3035196T3 true GR3035196T3 (en) | 2001-04-30 |
Family
ID=10729416
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GR20010400014T GR3035196T3 (en) | 1993-07-30 | 2001-01-10 | Method for treating multiple sclerosis |
Country Status (11)
Country | Link |
---|---|
US (1) | US5958409A (el) |
EP (2) | EP1004312A1 (el) |
JP (1) | JPH09509646A (el) |
AT (1) | ATE196849T1 (el) |
AU (1) | AU4719093A (el) |
DE (1) | DE69329558T2 (el) |
DK (1) | DK0710121T3 (el) |
ES (1) | ES2153384T3 (el) |
GR (1) | GR3035196T3 (el) |
PT (1) | PT710121E (el) |
WO (1) | WO1995003827A1 (el) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6552170B1 (en) * | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
US6270766B1 (en) | 1992-10-08 | 2001-08-07 | The Kennedy Institute Of Rheumatology | Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease |
US7070783B1 (en) * | 1995-05-09 | 2006-07-04 | The Mathilda And Terence Kennedy Institute Of Rheumatology | Small molecular weight TNF receptor multimeric molecule |
US7012060B1 (en) | 1995-07-14 | 2006-03-14 | Applied Research Systems Ars Holding N.V. | TNF receptor and steroid hormone in a combined therapy |
WO1997003686A1 (en) * | 1995-07-14 | 1997-02-06 | Applied Research Systems | Tnf receptor and steroid hormone in a combined therapy |
US7608262B2 (en) * | 1996-02-16 | 2009-10-27 | The Kennedy Institute Of Rheumatology | Methods of preventing or treating thrombosis with tumor necrosis factor antagonists |
TW555765B (en) | 1996-07-09 | 2003-10-01 | Amgen Inc | Low molecular weight soluble tumor necrosis factor type-I and type-II proteins |
US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
IL127851A0 (en) * | 1998-12-30 | 1999-10-28 | Applied Research Systems | Inhibition of TNF activity |
US6982089B2 (en) * | 1999-02-24 | 2006-01-03 | Tact Ip, Llc | Cytokine antagonists for neurological and neuropsychiatric disorders |
US8119127B2 (en) * | 1999-02-24 | 2012-02-21 | Tact Ip, Llc | Cytokine antagonists for neurological and neuropsychiatric disorders |
USRE45976E1 (en) * | 1999-02-24 | 2016-04-19 | Tact Ip, Llc | Methods of inhibiting the action of TNF for neurological conditions by administering etanercept intrathecally |
AU6929100A (en) * | 1999-08-23 | 2001-03-19 | Biocrystal Limited | Methods and compositions for immunotherapy of b cell involvement in promotion ofa disease condition comprising multiple sclerosis |
CA2448956C (en) * | 2001-05-30 | 2017-10-03 | Genentech, Inc. | Anti-ngf antibodies for the treatment of various disorders |
US20050175585A1 (en) * | 2001-06-11 | 2005-08-11 | Transition Therapeutics Inc. | Combination therapies using vitamin B12 and interferon for treatment of viral proliferative and inflammatory disesases |
US6908611B2 (en) * | 2001-06-11 | 2005-06-21 | Transition Therapeutics Inc. | Combination therapies using vitamin B12 and interferon for treatment of viral, proliferative and inflammatory diseases |
CN1332711C (zh) * | 2002-02-20 | 2007-08-22 | 埃米球科技有限公司 | 施用glp-1分子的方法 |
US9028822B2 (en) | 2002-06-28 | 2015-05-12 | Domantis Limited | Antagonists against TNFR1 and methods of use therefor |
ES2347239T3 (es) | 2002-12-02 | 2010-10-27 | Amgen Fremont Inc. | Anticuerpos dirigidos al factor de necrosis tumoral y usos de los mismos. |
US7101978B2 (en) | 2003-01-08 | 2006-09-05 | Applied Molecular Evolution | TNF-α binding molecules |
US7435799B2 (en) | 2004-01-08 | 2008-10-14 | Applied Molecular Evolution | TNF-α binding molecules |
US8236306B2 (en) * | 2004-12-18 | 2012-08-07 | Edward Lewis Tobinick | Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers |
JP2009531295A (ja) * | 2006-02-22 | 2009-09-03 | ユニバーシティ オブ チューリッヒ | 自己免疫疾患又は脱髄疾患を処置するための方法 |
US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
DK2970101T3 (en) | 2013-03-14 | 2018-08-20 | Alkermes Pharma Ireland Ltd | PRO-DRUGS OF FUMARATES AND THEIR USE IN TREATING DIFFERENT DISEASES |
CA2940845C (en) | 2014-02-24 | 2019-09-24 | Alkermes Pharma Ireland Limited | Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL98078A0 (en) * | 1991-05-07 | 1992-06-21 | Yeda Res & Dev | Pharmaceutical compositions comprising an anticytokyne |
DE10399036I1 (de) * | 1989-08-07 | 2004-04-01 | Peptide Technology Ltd | Bindeligande für Tumornekrosisfaktor. |
DK0939121T4 (da) * | 1989-09-12 | 2008-02-04 | Ahp Mfg B V | TNF-bindende proteiner |
US5656272A (en) * | 1991-03-18 | 1997-08-12 | New York University Medical Center | Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies |
DE4202665A1 (de) * | 1992-01-28 | 1993-07-29 | Schering Ag | Prostacyclin- und carbacyclinderivate als mittel zur behandlung von multipler sklerose |
-
1993
- 1993-07-30 AT AT93917954T patent/ATE196849T1/de active
- 1993-07-30 DK DK93917954T patent/DK0710121T3/da active
- 1993-07-30 WO PCT/GB1993/001614 patent/WO1995003827A1/en active IP Right Grant
- 1993-07-30 PT PT93917954T patent/PT710121E/pt unknown
- 1993-07-30 DE DE69329558T patent/DE69329558T2/de not_active Expired - Lifetime
- 1993-07-30 US US08/586,917 patent/US5958409A/en not_active Expired - Lifetime
- 1993-07-30 AU AU47190/93A patent/AU4719093A/en not_active Abandoned
- 1993-07-30 EP EP99203261A patent/EP1004312A1/en not_active Ceased
- 1993-07-30 ES ES93917954T patent/ES2153384T3/es not_active Expired - Lifetime
- 1993-07-30 EP EP93917954A patent/EP0710121B1/en not_active Expired - Lifetime
- 1993-07-30 JP JP7505635A patent/JPH09509646A/ja not_active Ceased
-
2001
- 2001-01-10 GR GR20010400014T patent/GR3035196T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
AU4719093A (en) | 1995-02-28 |
PT710121E (pt) | 2001-04-30 |
ES2153384T3 (es) | 2001-03-01 |
DE69329558T2 (de) | 2001-05-31 |
EP1004312A1 (en) | 2000-05-31 |
EP0710121A1 (en) | 1996-05-08 |
JPH09509646A (ja) | 1997-09-30 |
DK0710121T3 (da) | 2001-02-05 |
DE69329558D1 (de) | 2000-11-16 |
WO1995003827A1 (en) | 1995-02-09 |
EP0710121B1 (en) | 2000-10-11 |
US5958409A (en) | 1999-09-28 |
ATE196849T1 (de) | 2000-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GR3035196T3 (en) | Method for treating multiple sclerosis | |
EP0620739A4 (en) | Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists. | |
IT1261949B (it) | Composizione terapeutica a base di interferone umano, impiego di interferone umano in tale composizione e relativo metodo. | |
TW224053B (el) | ||
JPS57193412A (en) | Prevention of prostatic hyperplasia and therapeutical drug | |
NO179703C (no) | Fremgangsmåte for å belegge husholdningsgjenstander med et antivedhengningssjikt, og anvendelse av fremgangsmåten | |
ZA936799B (en) | Method for treating symptoms associated with premenstrual syndrome by administering vitamin D or A combination of calcium and vitamin D | |
AU7269294A (en) | Use of glucokinase inhibitors for the manufacture of a medicament for treating tumours | |
AU3945085A (en) | Semiconductor device and process for producing the same | |
IE882628L (en) | Substituted 2-phenyl-4-quinoline carboxylic acids | |
AU3236093A (en) | The use of ob-101 to treat inflammation | |
CA2016575A1 (en) | Method of aiding cessation of smoking | |
GR82494B (en) | Method for the preparation of 5-pyrimidinecarboxamides and thiocarboxamides and treatment of leukemia and tumors therewith | |
AU3235693A (en) | The use of ob-104 to treat inflammation | |
AU2861389A (en) | Disubstituted pyridines | |
AU1022195A (en) | Cytokine antibody for the treatment of sepsis | |
AU8634291A (en) | Process and device for the manufacture of high-pressure laminates | |
NO961226L (no) | Blandinger for forebyggelse og behandling av viralinduserte tumorer | |
WO1990004979A8 (en) | Method of preventing or reducing eosinophilia | |
AU3075692A (en) | Method of producing and treatment with tablet composition | |
PL310950A1 (en) | Novel imidazole quinoxalinones, method of obtaining them and their application | |
GB2271509B (en) | Antivenom immunesera | |
AU3189989A (en) | Process for the treatment of concrete | |
WO1993024117A3 (en) | Medicaments for the treatment of anxiety | |
CS309891A3 (en) | Compounds inhibiting the formation of tumorous necrotic factor, process of their preparation and their application |